Study Evaluating TTI-237 in Advanced Malignant Solid Tumors.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00195325|
Recruitment Status : Terminated
First Posted : September 19, 2005
Last Update Posted : March 26, 2007
|Condition or disease||Intervention/treatment||Phase|
|Tumors Neoplasms||Drug: TTI-237||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||45 participants|
|Intervention Model:||Factorial Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 1 Dose Escalation Study of TTI-237 Administered Intravenously (IV) Once Weekly in Subjects With Advanced Malignant Solid Tumors.|
|Study Start Date :||August 2005|
- To determine safety, tolerability, and MTD of TTI-237 - patients are monitored during the duration of their participation on the trial.
- Preliminary pharmacokinetics (during cycle 1) and anti-tumor activity of TTI-237 (approximately every 8 weeks).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00195325
|United States, Kentucky|
|Lexington, Kentucky, United States, 40536-0098|
|United States, Ohio|
|Cleveland, Ohio, United States, 44195|
|United States, Tennessee|
|Nashville, Tennessee, United States, 37232-6307|
|Study Director:||Medical Monitor||Wyeth is now a wholly owned subsidiary of Pfizer|